Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

NF-kB inhibition by DHMEQ: in vitro antiproliferative effects on pilocytic astrocytoma and concise review of the current literature

Full text
Author(s):
Candido, M. F. [1] ; Baldissera, G. C. [2] ; Medeiros, M. [1] ; Umezawa, K. [3] ; Brassesco, Maria Sol [4]
Total Authors: 5
Affiliation:
[1] Univ Sao Paulo, Dept Cell & Mol Biol, Ribeirao Preto Med Sch, Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, Ribeirao Preto Med Sch, Ribeirao Preto, SP - Brazil
[3] Aichi Med Univ, Dept Mol Target Med, Sch Med, Nagakute, Aichi - Japan
[4] FFCLRP USP, Dept Biol, Ave Bandeirantes 3900, BR-14040901 Ribeirao Preto, SP - Brazil
Total Affiliations: 4
Document type: Review article
Source: CHILD'S NERVOUS SYSTEM; v. 36, n. 11 MAY 2020.
Web of Science Citations: 0
Abstract

Introduction Pilocytic astrocytoma (PA) is the most common brain tumor that affects the pediatric population. Even though PA is benign and treatment only involves surgery, recurrent or unresectable tumors require chemo- and radiotherapy. Besides BRAF, CDKN2A, or IDH mutations, the hyperactivation of the nuclear factor NF-kappa B contributes to tumor growth and survival. Methods In the present study, we used publicly available data for the in silico analysis of NF-kappa B subunits (RELA, RELB, REL, NF-kappa B1, and NF-kappa B2) expression in PA samples. Besides, in vitro assays were performed to evaluate proliferation, migration, cell death, on the PA cell line Res286 comparing to human primary astrocytes. Sensitization to radiation therapy and temozolomide (TMZ) was also assayed. Results Our results showed that all the members of the NF-kB family are upregulated in PA datasets compared to normal brain tissues. Moreover, DHMEQ treatment significantly reduced cell growth and motility, while sensitized cells to ionizing radiation and TMZ, as previously seen in high-grade gliomas. Conclusions This drug presents a potential application in clinical practice for the treatment of recurrent or inoperable PA. Moreover, its use might assist adjuvant chemotherapy and reduce irradiation doses to avoid toxicity to the surrounding tissues. (AU)

FAPESP's process: 10/16652-9 - NF-kB inhibition in glioblastoma: in vitro and in vivo effects of DHMEQ in tumor chemoresistance, invasion and progression
Grantee:María Sol Brassesco Annichini
Support type: Scholarships in Brazil - Young Researchers
FAPESP's process: 10/50635-4 - NF-Kb inhibition in glioblastoma: in vitro and in vivo effects of DHMEQ in tumor chemoresistence, invasion and progression
Grantee:María Sol Brassesco Annichini
Support type: Research Grants - Young Investigators Grants